Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 2
2015 1
2019 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Turner NC, et al. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. N Engl J Med. 2015. PMID: 26030518 Free article. Clinical Trial.
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S, Scambia G, Villanucci A, Naglieri E, Ibarbia MA, Brusa F, Bourgeois H, Sorio R, Casado A, Reichert D, Dopchie C, De Rivas B, de Sande LM. Pignata S, et al. Among authors: dopchie c. Oncologist. 2021 Apr;26(4):e658-e668. doi: 10.1002/onco.13630. Epub 2021 Jan 3. Oncologist. 2021. PMID: 33289956 Free PMC article. Clinical Trial.
Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study.
Duck L, Demolin G, D'Hondt L, Dopchie C, Hendrickx K, Lannoye B, Bastin F, Lossignol D, Hamdan O, Lybaert W, Vandenhaute V, Regnault B, De Ruyter V, Geboes K. Duck L, et al. Among authors: dopchie c. Clin Ther. 2021 Dec;43(12):2136-2145.e2. doi: 10.1016/j.clinthera.2021.10.014. Epub 2021 Nov 26. Clin Ther. 2021. PMID: 34844770 Free article. Clinical Trial.
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Seront E, et al. Among authors: dopchie c. Ann Oncol. 2012 Oct;23(10):2663-2670. doi: 10.1093/annonc/mds057. Epub 2012 Apr 3. Ann Oncol. 2012. PMID: 22473592 Free article. Clinical Trial.
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H. Fontaine C, et al. Among authors: dopchie c. Breast Cancer Res Treat. 2019 Aug;176(3):607-615. doi: 10.1007/s10549-019-05259-z. Epub 2019 May 8. Breast Cancer Res Treat. 2019. PMID: 31069589 Clinical Trial.
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M, Khaksar S, Bera G, Birtle A, Dopchie C, Dourthe LM, Everaert E, Hatzinger M, Hercher D, Hilgers W, Matus G, Alvarez LG, Antoni L, Lukac M, Pissart G, Robinson P, Elliott T. Boegemann M, et al. Among authors: dopchie c. BMC Cancer. 2019 Jan 14;19(1):60. doi: 10.1186/s12885-019-5280-6. BMC Cancer. 2019. PMID: 30642291 Free PMC article.
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J. Machiels JP, et al. Among authors: dopchie c. J Clin Oncol. 2008 Nov 10;26(32):5261-8. doi: 10.1200/JCO.2008.16.9524. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794543 Clinical Trial.